Evaluation of IVIG for Prevention of Infections Occurring On-study and Treatment of Infection of Solid Organ Recipients With Secondary Antibody Deficiency: A Phase 2 Randomized Clinical Trial

Transplantation Direct 2026 Open access

Read full text
Authors: Elizabeth Sarmiento, Judith Montanchez, Ikram Ezzahouri, José M. Cifrián, Carlos Ortiz‐Bautista, Rosalía Laporta, Carles Bravo, Magdalena Salcedo, M. Rodriguez-Ferrero, J. González-Costello, J R Segovia, A. De Pablos
+21 more V Mora, Piedad Ussetti, Sonia Suárez López, Núria Fernández Sabé, Manuel Gomez-Bueno, Iago Sousa, Paula Navas, Pablo Díez‐Villanueva, M. Aguilar, Ainhoa Fernandez-Yunquera, Fernando Anaya, Patricia Muñóz, Maricela Valerio, Ana Mur, Alba Alarcon, Kristofer Limay, Marcos López‐Hoyos, Francisco Lopez, Ana Paula Vionnet, Manuel Serrano, Javier Carbone
DOI: 10.1097/txd.0000000000001928
Cited by: 2
References: 20

Abstract

Background. There is a paucity of data to guide the management of posttransplant secondary antibody deficiency (SAD). We aimed to evaluate the role of IVIG in solid organ recipients with SAD. Methods. A phase 2, randomized, multicenter, open-label study of solid organ recipients with severe infection and SAD defined as serum IgG

Fields of Study & Subjects

Immunodeficiency and Autoimmune Disorders Platelet Disorders and Treatments T-cell and B-cell Immunology

Publication details

Journal / source
Transplantation Direct
Publisher
Ovid Technologies (Wolters Kluwer Health)
Volume
12
Issue
4
Pages
e1928–e1928
Publication date
4 March 2026
Language
EN